FDA approves Synjardy (empagliflozin + metformin) to treat Type 2 Diabetes- Boehringer Ingelheim + Eli Lilly
The FDA has approved Synjardy (empagliflozin + metformin hydrochloride) tablets, from Boehringer Ingelheim and Eli Lilly, for the treatment of adults with type 2 diabetes (T2D). Synjardy is the third product containing empagliflozin to be approved by the FDA, following Jardiance (empagliflozin) and Glyxambi (empagliflozin/linagliptin).
Synjardy is a combination of empagliflozin and metformin – two medicines with complementary mechanisms of action – to help control blood glucose in people with T2D. Empagliflozin, a sodium glucose co-transporter-2 (SGLT2) inhibitor, removes excess glucose through the urine by blocking glucose re-absorption in the kidney. Metformin, a commonly prescribed initial treatment for T2D, lowers glucose production by the liver and its absorption in the intestine.
Comment: Synjardy was also approved by the European Medicines Agency in May 2015.